AlloSource announced positive prospective clinical outcomes for the repair of focal articular cartilage defects in the knee using ProChondrix CR, a full-thickness intact living cellular articular cartilage allograft.
The prospective clinical study recorded pre- and postoperative overall patient function and pain, functions in daily living/sports and quality of life. These patient-reported outcomes showed sustained positive result scores with statistical significance achieved at 6, 12, 24 and 36 months postoperatively. Most notably at 36 months, International Knee Documentation Committee scores improved by 86.3% and KOOS Quality of Life scores improved by 132.5% from the preoperative scores.
ProChondrix CR is a living intact hyaline cartilage product that contains functional chrondrocytes and other biological components necessary for repair and replacement of damaged articular cartilage tissue. Created with AlloSource’s proprietary cartilage cryopreservation process, ViaTrue, ProChondrix CR has an average of 94.97% chondrocyte viability after two years of cryopreserved storage. The two-year shelf life helps to alleviate inventory management challenges and provides surgeons with more flexibility for their patients.
“ProChondrix CR has demonstrated promising data in the laboratory. This clinical data continues to tell the story of the positive impact ProChondrix CR can have on patient recovery,” said Carolyn Rorick, AlloSource Senior Director Product Development, Innovation and Clinical Affairs. “The study is ongoing, so we will continue to gather additional data to confirm the longer-term results.”
AlloSource announced positive prospective clinical outcomes for the repair of focal articular cartilage defects in the knee using ProChondrix CR, a full-thickness intact living cellular articular cartilage allograft.
The prospective clinical study recorded pre- and postoperative overall patient function and pain, functions in daily...
AlloSource announced positive prospective clinical outcomes for the repair of focal articular cartilage defects in the knee using ProChondrix CR, a full-thickness intact living cellular articular cartilage allograft.
The prospective clinical study recorded pre- and postoperative overall patient function and pain, functions in daily living/sports and quality of life. These patient-reported outcomes showed sustained positive result scores with statistical significance achieved at 6, 12, 24 and 36 months postoperatively. Most notably at 36 months, International Knee Documentation Committee scores improved by 86.3% and KOOS Quality of Life scores improved by 132.5% from the preoperative scores.
ProChondrix CR is a living intact hyaline cartilage product that contains functional chrondrocytes and other biological components necessary for repair and replacement of damaged articular cartilage tissue. Created with AlloSource’s proprietary cartilage cryopreservation process, ViaTrue, ProChondrix CR has an average of 94.97% chondrocyte viability after two years of cryopreserved storage. The two-year shelf life helps to alleviate inventory management challenges and provides surgeons with more flexibility for their patients.
“ProChondrix CR has demonstrated promising data in the laboratory. This clinical data continues to tell the story of the positive impact ProChondrix CR can have on patient recovery,” said Carolyn Rorick, AlloSource Senior Director Product Development, Innovation and Clinical Affairs. “The study is ongoing, so we will continue to gather additional data to confirm the longer-term results.”
Copy to clipboard 
